MedTrace Logo

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

NCT06572722 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-04-27

No results posted yet for this study

Summary

This trial is a randomized, multicenter, open label phase II clinical study. The main objective is to evaluate the efficacy of three perioperative immunotherapy modalities (atezolizumab adjuvant therapy, nivolumab neoadjuvant therapy, pembrolizumab neoadjuvant+adjuvant therapy) in early-stage resectable NSCLC patients. The enrolled patients are randomly assigned in a 1:1:1 ratio to receive relevant treatment in the three perioperative immunotherapy groups mentioned above, and undergoing short-term pathological efficacy evaluation and long-term prognosis follow-up after surgery.

Conditions

Interventions

DRUG

Atezolizumab

atezolizumab adjuvant therapy

DRUG

Nivolumab

nivolumab neoadjuvant therapy

DRUG

Pembrolizumab

pembrolizumab neoadjuvant+adjuvant therapy

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Haiquan Chen, M.D. · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2026-09-01
Completion
2029-09-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06572722 on ClinicalTrials.gov